Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma

References

• Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-38
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-25
   PubMed Web of Science ®Google Scholar
• Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med 2012;185:709-14
   PubMedGoogle Scholar
• Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014;2:525-536.e521
   PubMed Web of Science ®Google Scholar
• Garcia G, Taillé C, Laveneziana P, et al. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev 2013;22:251-7
   PubMedGoogle Scholar
• Pavord ID. Non-eosinophilic asthma and the innate immune response. Thorax 2007;62:193-4
   PubMed Web of Science ®Google Scholar
• Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological Properties and Role in Health and Disease. Clin Exp Allergy 2008;38:709-50
   PubMed Web of Science ®Google Scholar
• Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009;101:81-121
   PubMed Web of Science ®Google Scholar
• van Veen IH, ten Brinke A, Gauw SA, et al. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009;124:615-17; e612
   PubMed Web of Science ®Google Scholar
• Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-94
   PubMed Web of Science ®Google Scholar
• Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997;155:1501-8
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhu J, Bandi V, et al. Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 2007;62:475-82
   PubMed Web of Science ®Google Scholar
• Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21
   PubMed Web of Science ®Google Scholar
• Wegmann M. Targeting eosinophil biology in asthma therapy. Am J Respir Cell Mol Biol 2011;45:667-74
   PubMed Web of Science ®Google Scholar
• Molfino NA, Gossage D, Kolbeck R, et al. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012;42:712-37
   PubMed Web of Science ®Google Scholar
• Huston MM, Moore JP, Mettes HJ, et al. Human B cells express IL-5 receptor messenger ribonucleic acid and respond to IL-5 with enhanced IgM production after mitogenic stimulation with Moraxella catarrhalis. J Immunol 1996;156:1392-401
   PubMed Web of Science ®Google Scholar
• Rosenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:1245-6
   Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133-41
   PubMed Web of Science ®Google Scholar
• Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004;103:2939-41
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129:456-463.e453
   PubMed Web of Science ®Google Scholar
• Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 1999;49:779-90
   PubMed Web of Science ®Google Scholar
• Zhang J, Kuvelkar R, Murgolo NJ, et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 1999;11:1935-44
   PubMed Web of Science ®Google Scholar
• Kips JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma. Am J Respir Crit Care Med 2003;167:1655-9
   PubMed Web of Science ®Google Scholar
• Leckie MJ, Brinke AT, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response. Lancet 2000;356:2144-8
   PubMed Web of Science ®Google Scholar
• van Drunen CM, Reinartz S, Wigman J, et al. Inflammation in chronic rhinosinusitis and nasal polyposis. Immunol Allergy Clin North Am 2009;29:621-9
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of reslizumab Treatment in patients with moderate to severe asthma. Available from: https://clinicaltrials.gov/ct2/show/NCT01508936
   Google Scholar
• A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 Years of Age) with eosinophilic asthma. Available from: https://clinicaltrials.gov/ct2/show/NCT01270464
   Google Scholar
• Corren J, Weinsten S, Janka L, et al. A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. In: European Respiratory Society Annual Congress; 10 September 2014; Munich, Germany; European Respiratory Journal 2014
   Google Scholar
• Bjermer L, Lemière C, Maspero JF, et al. A randomized phase 3 sutdy of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. In: European Respiratory Society Annual Congress; 7 September 2014; Munich, Germany; European Respiratory Journal 2014
   Google Scholar
• Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013;131:461-7; e461-465
   PubMed Web of Science ®Google Scholar
• Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004;114:1449-55
   PubMed Web of Science ®Google Scholar
• Zabeau L, Van der Heyden J, Broekaert D, et al. Neutralizing monoclonal antibodies can potentiate IL-5 signaling. Eur J Immunol 2001;31:1087-97
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013;132:1086-96; e1085
   PubMed Web of Science ®Google Scholar
• Nair P. Anti-Interleukin-5 monoclonal antibody to treat severe eosinophilic Asthma. N Engl J Med 2014;371:1249-51
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012;11:958-72
   PubMed Web of Science ®Google Scholar
• Busse WW. The relationship of airway hyperresponsiveness and airway inflammation: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010;138:4S-10S
   PubMed Web of Science ®Google Scholar
• McCallister JW. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy? Am J Respir Crit Care Med 2011;184:1096-7
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 2014;133:921-3
   PubMed Web of Science ®Google Scholar
• Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008;121:1473-83; 1483 e1471-1474
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98
   PubMed Web of Science ®Google Scholar
• Hargreave FE, Nair P. Point: is measuring sputum eosinophils useful in the management of severe asthma? Yes. Chest 2011;139:1270-3
   Google Scholar
• Nair P. What is an ‘eosinophilic phenotype’ of asthma? J Allergy Clin Immunol 2013;132:81-3
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med 2014;371:1198-207
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med 2014;371:1189-97
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RAJr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014;2(11):891-901
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009;180:817-22
   PubMed Web of Science ®Google Scholar
• Wilson AM, McFarlane LC, Lipworth BJ. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest 1998;114:1022-7
   Google Scholar
• Spector SL, Tan RA. Is a single blood eosinophil count a reliable marker for ‘eosinophilic asthma?’. J Asthma 2012;49:807-10
   PubMed Web of Science ®Google Scholar
• Katz LE, Gleich GJ, Hartley BF, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014;11:531-6
   PubMedGoogle Scholar
• Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013;132:72-80
   PubMed Web of Science ®Google Scholar
• Nair P, Zhang Q, Brennan JD. A perspective on point-of-care tests to detect eosinophilic bronchitis. J Asthma 2014. [Epub ahead of print]
   Google Scholar